Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Hypothyroidism
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • The sustained maintenance of serum levels of PEG-IFN allows once-weekly dosing. The efficacy and tolerability profile was qualitatively similar to standard IFN-alpha, and adverse events were mostly mild to moderate in nature.

publication date

  • November 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdf288

PubMed ID

  • 12419754

Additional Document Info

start page

  • 1799

end page

  • 805

volume

  • 13

number

  • 11